What is Levicept?
Levicept is a biopharmaceutical company dedicated to addressing the unmet needs of individuals suffering from chronic pain, particularly that associated with osteoarthritis. The company's core mission is to develop and deliver effective, well-tolerated analgesic treatments that offer a safer alternative to prolonged opiate use and the adverse effects commonly linked to non-steroidal anti-inflammatory drugs (NSAIDs). By focusing on innovative pain management strategies, Levicept aims to improve the quality of life for patients seeking reliable and less risky pain relief options.
How much funding has Levicept raised?
Levicept has raised a total of $16M across 1 funding round:
Series A
$16M
Series A (2014): $16M with participation from Gilde Healthcare, Advent Life Sciences, and Index Ventures
Key Investors in Levicept
Gilde Healthcare
Gilde Healthcare is a specialized investment firm with a strong focus on the healthcare sector, managing substantial assets across venture, growth, and private equity strategies. Their investment in Levicept aligns with their mission to support businesses that enhance patient care and reduce healthcare costs.
Advent Life Sciences
Advent Life Sciences is a venture capital firm that invests in early-stage life science companies. Their backing of Levicept suggests a belief in the company's innovative approach to pain management and its potential for significant impact in the biopharmaceutical market.
Index Ventures
Index Ventures is a global venture capital firm known for investing in disruptive companies from seed to IPO. Their participation in Levicept's funding round indicates confidence in the company's long-term vision and its potential to scale and lead in the therapeutic pain market.
What's next for Levicept?
The recent major strategic investment signals a pivotal growth phase for Levicept. This capital infusion is expected to accelerate the company's research and development initiatives, potentially advancing its pipeline of analgesic solutions through further clinical trials and regulatory processes. The strategic nature of this financing suggests a focus on market penetration and the scaling of operations to meet the significant demand for safer chronic pain management alternatives. Levicept's trajectory indicates a strong commitment to becoming a leader in the pain therapeutics sector.
See full Levicept company page
